October 30, 2025
From shot to shock
Moderna, the company that helped save the world, has unraveled
From miracle shots to market shock: hope vs. “pump‑and‑dump” rage
TLDR: Moderna’s value cratered and government contracts were cut, leaving the once‑hero company fighting for its future while touting cancer‑vaccine hope. Comments split between “pump‑and‑dump” accusations, backlash over mandates, and believers betting the science still wins—making this collapse a high‑stakes drama for medicine and markets alike.
Moderna’s glow‑up has turned into a glow‑down. After a pandemic‑era high, the company’s value plunged about 90% (yes, a full Sony), layoffs are swirling, and the U.S. Health and Human Services—now led by vaccine skeptic Robert F. Kennedy Jr.—scrapped $766 million in bird‑flu shot prep contracts, per STAT. Cue the comments section going feral.
On one side, optimists like pizzathyme insist the science isn’t dead: mRNA (a way to teach your body to fight disease) is still progressing, with hopes pinned on a personalized cancer vaccine. On the other, reenorap fumes that “politicians oversold it,” arguing mandates soured the public—sparking a pile‑on of civil‑liberties talk and “we were forced” memes. Then the conspiracy‑curious show up: Projectiboga drops a “karma” bomb and a story about rival tech getting sidelined. Skeptics like t1234s go full Wall Street meme with “looked like a pump and dump.”
Amid the crossfire, bena plays hall monitor: Earth has 8 billion people, we can do many things at once. The drama is electric—“from shot to shock” jokes, stock charts turned rollercoasters, and armchair CEOs everywhere. Whether Moderna bounces back with $6B in cash and a billion‑dollar Covid shot, or shrinks into something smaller, the comments have already decided their own verdicts.
Key Points
- •Moderna’s plan to translate Covid-era gains into a broad mRNA portfolio has stalled, with no new blockbuster products.
- •Covid vaccine sales have slumped, prompting Wall Street pressure on Moderna to cut spending and restructure.
- •HHS, led by Robert F. Kennedy Jr., canceled $766 million in bird flu preparedness contracts affecting Moderna.
- •Moderna’s market value has fallen by over 90% from its 2021 peak to around $10 billion; layoffs and restructurings have occurred.
- •Despite setbacks, Moderna retains $6 billion in cash, over $1 billion in annual Covid shot sales, and a promising cancer vaccine candidate.